OCON Therapeutics

Company Overview

Snapshot

Founded in March 2011, OCON Therapeutics operates with 11–50 employees and has raised $24.5M across 8 funding rounds from 12 investors. In June 2024, the company secured $10M in funding, with Rhia Ventures participating as a lead investor.

Business overview

OCON Therapeutics is a Health Tech & Life Sciences company focused on women's health. It develops, manufactures, and commercializes products based on its proprietary intrauterine ball (IUB) platform. This technology, made from super-elastic nitinol, serves as a carrier for multiple drugs to the uterus, addressing conditions such as abnormal uterine bleeding, heavy menstrual bleeding, myomas, fibroids, and infertility. The company's core products include the IUB Ballerine, IUB SEAD, and IUB PRIMA, targeting patients, providers, and distributors across global markets including Australia, Africa, Asia, Europe, Americas, South America, and China.

Strategic signal

In June 2024, OCON Therapeutics raised $10M in funding, signaling continued investor confidence in its innovative intrauterine drug delivery platform for women's health. This capital infusion is crucial for advancing its product pipeline and expanding market reach, particularly for its IUD and women's health solutions, indicating a strong forward trajectory despite its non-active status as of April 2026.

Company Intelligence Q&A

What is the primary focus of OCON Therapeutics?

OCON Therapeutics focuses on women's health, developing and commercializing products based on its proprietary and patented intrauterine ball (IUB) platform for drug delivery to the uterus.

When did OCON Therapeutics last raise funding?

OCON Therapeutics raised $10M in funding in June 2024. Rhia Ventures was a lead investor in this round.

What is the IUB Ballerine?

The IUB Ballerine is OCON Therapeutics' flagship product, utilizing a spherical intrauterine device made from nitinol for hormone-free contraception and drug delivery.

Has OCON Therapeutics received any industry recognition?

OCON Healthcare was awarded as a Technology Pioneer by the World Economic Forum in May 2022 and received the 2021 Global Enabling Technology Leadership Award from Frost & Sullivan in April 2021.

What strategic partnerships has OCON Therapeutics formed?

In June 2022, OCON Healthcare signed an exclusive agreement with BioGenuine to market its products in China and Southeast Asian countries, expanding its global distribution.